Around the World's Markets: London
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.LEADING SHARES rose for a second day on the back of a strong rebound in leading drug stocks. The FTSE 100 extended its rebound from Monday's four-month lows to close up 34.4 points or 0.6 per cent at 6,297.2.
The advance was due to sharp gains of more than 4 per cent each in drug stocks Glaxo Wellcome and SmithKline Beecham.
The two rebounded from their lowest levels since late 1998 to lift the index by 21 points. "The story is that these stocks were just amazingly cheap," said one analyst. Market Report, page 21
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments